1. [Pediatric medulloblastoma: Retrospective series of 52 patients]
- Author
-
C, Vigneron, D, Antoni, A, Coca, N, Entz-Werlé, P, Lutz, A, Spiegel, S, Jannier, C, Niederst, D, Jarnet, P, Meyer, P, Kehrli, and G, Noël
- Subjects
Male ,Neoplasm, Residual ,Adolescent ,Infant ,Prognosis ,Disease-Free Survival ,Methotrexate ,Chemotherapy, Adjuvant ,Vincristine ,Child, Preschool ,Procarbazine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Female ,Radiotherapy, Adjuvant ,France ,Cerebellar Neoplasms ,Child ,Follow-Up Studies ,Medulloblastoma ,Retrospective Studies - Abstract
Retrospective analysis of the results of 52 children irradiated for a medulloblastoma.Between 1974 and 2012, 52 children with an average age of 6 years and a half (11 months-17 years and a half) were treated with surgery then with radiotherapy at the Comprehensive Cancer Centre of Strasbourg (France). For 44 children, the treatment consisted of a chemotherapy.After a mean follow-up of 106.6 months (7-446 months), 13 relapses and 24 deaths were observed. Overall survival at 5 years and 10 years were 62% and 57%, respectively. Disease-free survival at 5 years and 10 years were 80% and 63%, respectively. Univariate analysis found the following adverse prognostic factors: the existence of a postoperative residue, the positivity of the cerebrospinal fluid, the metastatic status and medulloblastoma of high-risk. Positivity of the cerebrospinal fluid remains a negative factor in multivariate analysis.These results confirm the survival rate obtained by a conventional approach (surgery then irradiation). Insufficiency of results and rarity of medulloblastoma require the establishment of international protocols.
- Published
- 2015